128 related articles for article (PubMed ID: 29273587)
1. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.
Jirkovský E; Jirkovská A; Bureš J; Chládek J; Lenčová O; Stariat J; Pokorná Z; Karabanovich G; Roh J; Brázdová P; Šimůnek T; Kovaříková P; Štěrba M
J Pharmacol Exp Ther; 2018 Mar; 364(3):433-446. PubMed ID: 29273587
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Schroeder PE; Hasinoff BB
Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
[TBL] [Abstract][Full Text] [Related]
3. Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium.
Kovarikova P; Pasakova-Vrbatova I; Vavrova A; Stariat J; Klimes J; Simunek T
J Pharm Biomed Anal; 2013 Mar; 76():243-51. PubMed ID: 23339990
[TBL] [Abstract][Full Text] [Related]
4. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
[TBL] [Abstract][Full Text] [Related]
6. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
Popelová O; Sterba M; Hasková P; Simůnek T; Hroch M; Guncová I; Nachtigal P; Adamcová M; Gersl V; Mazurová Y
Br J Cancer; 2009 Sep; 101(5):792-802. PubMed ID: 19623174
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
[TBL] [Abstract][Full Text] [Related]
9. The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.
Schroeder PE; Patel D; Hasinoff BB
Drug Metab Dispos; 2008 Sep; 36(9):1780-5. PubMed ID: 18515330
[TBL] [Abstract][Full Text] [Related]
10. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
11. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
12. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Hasinoff BB
Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
[TBL] [Abstract][Full Text] [Related]
14. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
[TBL] [Abstract][Full Text] [Related]
15. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
[TBL] [Abstract][Full Text] [Related]
16. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Bures J; Jirkovska A; Sestak V; Jansova H; Karabanovich G; Roh J; Sterba M; Simunek T; Kovarikova P
Toxicology; 2017 Dec; 392():1-10. PubMed ID: 28941780
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Schroeder PE; Jensen PB; Sehested M; Hofland KF; Langer SW; Hasinoff BB
Cancer Chemother Pharmacol; 2003 Aug; 52(2):167-74. PubMed ID: 12750840
[TBL] [Abstract][Full Text] [Related]
18. In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization.
Mody H; Vaidya TR; Ait-Oudhia S
Sci Rep; 2023 Feb; 13(1):3100. PubMed ID: 36813809
[TBL] [Abstract][Full Text] [Related]
19. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Jirkovská A; Karabanovich G; Kubeš J; Skalická V; Melnikova I; Korábečný J; Kučera T; Jirkovský E; Nováková L; Bavlovič Piskáčková H; Škoda J; Štěrba M; Austin CA; Šimůnek T; Roh J
J Med Chem; 2021 Apr; 64(7):3997-4019. PubMed ID: 33750129
[TBL] [Abstract][Full Text] [Related]
20. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo.
Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M
Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
